Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator

Circulation

Volumn 126, Issue 20, 2012, Pages 2402-2407

  Rho, Robert W ^a   Patton, Kristen K ^a   Poole, Jeanne E ^a   Cleland, John G ^b   Shadman, Ramin ^a   Anand, Inder ^c   Maggioni, Aldo Pietro ^d   Carson, Peter E ^e   Swedberg, Karl ^f   Levy, Wayne C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Italian Association of Hospital Cardiologists   (Italy)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

cardiac resynchronization therapy; death, sudden; defibrillators; heart failure; pump failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM SPARING DIURETIC AGENT;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SEX DIFFERENCE; SUDDEN DEATH;

AGED; COHORT STUDIES; DEATH, SUDDEN; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PRIMARY PREVENTION; REGISTRIES; RISK FACTORS; SEX CHARACTERISTICS; SURVIVAL RATE; WASHINGTON;

EID: 84869209133     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.069245     Document Type: Article

References (32)

1. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Shoenfeld MH, Silka MJ, Stevenson LW, Sweeney MMO; American College of Cardiology/American Heart Association Task Force on Practice; American Association for Thoracic Surgery; Society of Thoracic Surgeons. The ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm. 2008;5:934-055.
2. Henyan NN, White CM, Gillespie EL, Smith K, Coleman CI, Kluger J. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. J Intern Med. 2006;260:467-473. (Pubitemid 44571135)
3. Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, Machado C. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009; 169:1500-1506.
4. Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, Santarelli P, Di Biase L, Natale A. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm. 2009;7:876-82.
5. Lilli A, Ricciardi G, Porciani MC, Perini AP, Pieragnoli P, Musilli N, Colella A, Del Pace S, Michelucci A, Turreni F, Sassara M, Achilli A, Barold SS, Padeletti L. Cardiac resynchronization therapy: gender related differences in left ventricular reverse remodeling. Pacing Clin? Electrophysiol. 2007;30:1349-1355. (Pubitemid 350043826)
6. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall JW, McNitt S, Zareba W, Solomon S, Steinberg JS. Cardiac resynchronization therapy is more effective in women than in men. J Am Coll Cardiol. 2011;57:813-820.
7. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sappo JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild to moderate heart failure. N Engl J Med. 2010;363:2385-2395.
8. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433. (Pubitemid 43739439)
9. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA, Levy WC. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116:392-398. (Pubitemid 47196544)
10. Packer M, O-Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study group. N Engl J Med. 1996;335:1107-1114. (Pubitemid 26330964)
11. Sullivan MD, Levy WC, Crane BA, Russo JE, Spertus JA. Usefulness of depression to predict time to combined end-point of transplant or death for outpatients with advanced heart failure. Am J Cardiol. 2004;94:1577-1580. (Pubitemid 40268470)
12. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675. (Pubitemid 33126822)
13. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet. 2003; 362:7-13.
14. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, Tavazzi L, Latini R, Cohn J. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail. 2005;11:91-98. (Pubitemid 40269782)
15. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, Maggioni AP, Anand I, Poole-Wilson PA, Fishbein DP, Johnson G, Anderson J, Mark DB, Bardy GH. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation. 2009;120:835-842.
16. May HT, Horne BD, Levy WC, Kfoury AG, Rasmusson KD, Linker DT, Mozaffarian D, Anderson JL, Renlund DG. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol. 2007; 100:697-700. (Pubitemid 47223146)
17. Levy WC, Aaronson K, Dardas T. Does peak oxygen consumption add to the Seattle Heart Failure Model? Circulation. 2007, 116:II-505.
18. Ky B, French B, McCloskey K, Rame E, McIntosh E, Shahi P, Dries DL, Tang W, Wu AHB, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4:180-187.
19. Fine JP, Gray RJ. A proportional hazards model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94:496-509.
20. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defi-brillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883. (Pubitemid 34984635)
21. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
22. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237. (Pubitemid 40110811)
23. Santangeli P, Pelargonio G, Russo AD, Casella M, Bisceglia C, Bartoletti S, Santarelli P, Di Biase L, Natale A. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm. 2010;7:876-882.
24. Kannel WB. Incidence and epidemiology of heart failure. Heart Failure Reviews. 2000;5:167-173.
25. Yap YG, Duong T, Bland M, Malik M, Torp-Pedersen C, Kober L, Connolly SJ, Marchant B, Camm J. Temporal trends on the risk of arrhythmic versus non-arrhythmic deaths in high-risk patients after myo-cardial infarction: a combined analysis from multicenter trials. Eur H J. 2005;26:1385-1393. (Pubitemid 41373515)
26. Dash R, Frank KF, Carr AN, Moravec CS, Kranias EG. Gender influences on sarcoplasmic reticulum calcium handling in failing human myocardium. J Mol Cell Cardiol. 2001;33:1345-1353. (Pubitemid 32613426)
27. Vizgirda VM, Wahler GM, Sondgeroth KL, Ziolo MT, Schwertz DW. Mechanism of sex differences in rat cardiac myocyte response to beta-adrenergic stimulation. Am J Physiol Heart Circx Physiol. 2002;282: H256-H263. (Pubitemid 34654157)
28. Song M, Helguera G, Eghbali M. Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones J Biol Chem. 2001;276:31883-31890.
29. Nakagawa M Ooie T, Ou B, Ichinose M, Takahashi N, Hara M, Yonemochi H, Saikawa T. Gender differences in autonomic modulation of ventricular repolarization in humans. J Cardiovasc Electrophysiol. 2005;16:278-284. (Pubitemid 40404592)
30. Wei SK, McCurley JM, Hanlon SU, Haigney MC. Gender differences in NA/Ca exchanger current and beta-adrenergic responsiveness in heart failure in pig myocytes. Ann NY Acad Sci. 2007;1099:183-189. (Pubitemid 47092592)
31. Lee DS, Birnie D, Cameron D, Crystal E, Dorian P, Gula LJ, Healey JS, Janmohammed A, Khaykin Y, Krahn AD, LeFeuvre C, Simpson CS, Yee R, Hardy J, Slaughter PM, Chen Z, Alter DA, Laupacis A, Tu JV. Design and implementation of a population-based registry of implantable cardio-verter defibrilltors in Ontario. Heart Rhyhthm. 2008;5:1250-1256.
32. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappen-berger L, Klein W, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study investigators, The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549. (Pubitemid 40517094)